The U.S. Food and Drug Administration (FDA) has approved Levemir (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes, making it the first and only basal insulin analog for use in this young patient group. With the expansion of its pediatric indication… Read more
Two new phase 3 studies published in The Lancet show that ultra long acting insulin, Degludec, an investigational compound from Novo Nordisk, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.
The two studies included in total 1,635 participants and investigated insulin degludec compared to insulin… Read more
Dr. Jovanovic even recommends using Levemir injections at night to women using insulin pumps, as she prefers the assurance of a basal shot… Read more
The U.S. FDA has approved Novo Nordisk’s Levemir insulin (insulin detemir [rDNA origin] injection) for use by pregnant women with diabetes, giving it a Category B classification, indicating that it does not increase the risk of harm to the unborn baby.
The label update makes Levemir the first and only basal insulin analog to have this classification… Read more
“Paula Deen is not the diabetes poster child,” said Ambre Morely, associate director of product communications at Novo Nordisk. “She’s an everyday person with type 2 diabetes… Read more
The blogosphere was thrumming about whether the Food Network’s down-home Southern queen, Paula Deen, has Type 2 diabetes. Yes, by now you know she does. It doesn’t bother me that she kept it “close to my chest” as she announced … Read more
Paula Deen has been privately suffering from type 2 diabetes for three years. Now she’s gone public with both her diabetes and her treatment with Victoza… Read more
After days of rumors regarding Paula Deen’s diabetes diagnosis, the woman dubbed the Queen of Southern Cuisine has announced that she and her sons have partnered up with Novo Nordisk to launch Diabetes in a New Light™, a national initiative to help adults find simple ways… Read more
A study released by Novo Nordisk at the International Diabetes Federation (IDF) 21st World Diabetes Congress in Dubai has found that the combination insulin degludec/insulin aspart, currently being developed, significantly reduced hypoglycemia in type 1 diabetes and type 2 diabetes patients… Read more
Data from the A1chieve® study, evaluating adverse events and effectiveness of Novo Nordisk insulins (NovoMix 30, Levemir and NovoRapid) in 66,726 people with type 2 diabetes, shows that type 2 diabetes patients can significantly improve their blood glucose control with a low occurrence of low blood sugar (hypoglycemia)… Read more